Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Radiotherapy and Imaging
  • View Item
  • Home
  • ICR Divisions
  • Radiotherapy and Imaging
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Molecular radiotheranostics for neuroendocrine tumours.

Thumbnail
View/Open
Supporting information (63.31Kb)
Publication Date
2017-10
ICR Author
Flux, Glenn
Marsden,
Author
Navalkissoor, S
Flux, G
Bomanji, J
Type
Journal Article
Metadata
Show full item record
Abstract
This article discusses the important role of nuclear medicine imaging and therapy in the management of neuroendocrine tumours (NETs). Somatostatin receptor scintigraphy has a high impact on patient management versus conventional imaging. Molecular radiotherapy is an important part of the management of patients with NETs. Selection of patients for molecular radiotherapy in NETs is based on uptake on their radionuclide imaging study. The imaging agent has the same mechanism of uptake as the therapeutic agent. Thus, the imaging study preselects patients that are likely to concentrate radiation within their tumours.
URL
https://repository.icr.ac.uk/handle/internal/1352
Collections
  • Radiotherapy and Imaging
Version of record
10.7861/clinmedicine.17-5-462
Subject
Humans
Neuroendocrine Tumors
Radionuclide Imaging
Research team
Radioisotope Physics
Language
eng
License start date
2017-10
Citation
Clinical medicine (London, England), 2017, 17 (5), pp. 462 - 468

Browse

All of ICR repositoryICR DivisionsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.